Cargando…
Noncytotoxic Pyrrolobenzodiazepine–Ciprofloxacin Conjugate with Activity against Mycobacterium tuberculosis
[Image: see text] The development of new antitubercular agents for the treatment of infections caused by multidrug-resistant (MDR) Mycobacterium tuberculosis is an urgent priority. Pyrrolobenzodiazepines (PBDs) are a promising class of antibacterial agents that were initially discovered and isolated...
Autores principales: | Picconi, Pietro, Jeeves, Rose, Moon, Christopher William, Jamshidi, Shirin, Nahar, Kazi S., Laws, Mark, Bacon, Joanna, Rahman, Khondaker Miraz |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical Society
2019
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6921268/ https://www.ncbi.nlm.nih.gov/pubmed/31867477 http://dx.doi.org/10.1021/acsomega.9b00834 |
Ejemplares similares
-
Covalent DNA Binding Is Essential for Gram-Negative Antibacterial Activity of Broad Spectrum Pyrrolobenzodiazepines
por: Picconi, Pietro, et al.
Publicado: (2022) -
From Anthramycin to Pyrrolobenzodiazepine (PBD)‐Containing Antibody–Drug Conjugates (ADCs)
por: Mantaj, Julia, et al.
Publicado: (2016) -
Antibody–Drug Conjugates—A Tutorial Review
por: Baah, Stephanie, et al.
Publicado: (2021) -
Pyrrolobenzodiazepines (PBDs) Do Not Bind to DNA G-Quadruplexes
por: Rahman, Khondaker M., et al.
Publicado: (2014) -
Antistaphylococcal activity of DNA-interactive pyrrolobenzodiazepine (PBD) dimers and PBD-biaryl conjugates
por: Rahman, Khondaker M., et al.
Publicado: (2012)